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Background: The immunosuppressa~~ts rapamycin, 
asconlycirl, FK5Of3, aud cyclosporin act by binding to :I 
class of cytosolic proteins, the irrununophilins. In the case 
of FKSOh, ascomycin and cyclosporin, the target of the 
ilrlrnunophilin-inl~~lLlIlosuppressant complex is cal- 
cineurin; in the case of rapamycin, the target is FRAP 
(TOWKAFTI). Kaparnyciu, asconlyciu and FK.506 have 
a common domain rcspousible for binding to FKBP12, 
their cellular receptor, and different effector domains that 
determine the target of the complex. Both domains are 
necessary for signal transduction and biological activity 
Results: A hybrid molecule containing the rapmiyciIi- 
FK506-ascomycin binding domain and a peptidc tether 
has been designed, synthesized and biolo@ly evaluated. 
The designed compound binds to FKBP12 bvith high 
affEnity but has no biological activity, as expected from its 
tack of an effector domain. 
Conclusions: The designed raparnycin-based FKHPI 2 
l&and exhibits powerful binding properties but, unlike 
rapamycin, shows no activity in IL-6 dependent B-cell 
proliferation and, in contrast to FK506, shows no activity 
in the lL-2 reporter assay. The modular nature of this 
designed molecule should make it postible to generate a 
series of compounds with effector domains for targeting 
either cslcineurin or FRAP (TOR/RAFTl) or both, as 
poteutial biological tools and immunosuppressive agents. 
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Introduction 
Rapamycin (compound 1, Fig. 1) 111, ascomycin (com- 
pound 2) [2], FK506 (compound 3) [3], and cyclosporin 
(compound 4) [4] are naturally-occurriIlg substances with 
potent immunosuppressive properties [5-S]. These con- 
pounds bind tightly to the inmmnophilins, a class of 
cytosolic proteins, forming complexes which in turn serve 
as ligands for other cellular targets involved in signal trans- 
duction 1.5-8 1. Cyclosporin binds to cyclophilin [ 91, while 
ascomycin, FK506 and rapannycin all bind to FKBP12 
[ 10,l 11. The target of the cyclophilill-cyclosporin, 
FKBPl2-ascomycin and FKBPl2-FK506 complexes is 
calcineurin 1121, whereas that of the FKBPI 2-rapamycin 
complex is a recently-characterized cellular target named 
FRAP 1131, also called TOK 1141 or KAFTI 1151. 
Binding of the FKBP12-rapamycin complex to FKAP 
signals the arrest of the cell cycle. 
The structures of FKBP12 and its ligands, FK506, 
ascomycin, and rapamycin have been elucidated by 
NMR spectroscopy 116,171 and X-ray crystallography 
[18,19]. Together with extensive biological results these 
studies established that each of these novel immunosup- 
pressants bears two distinct domains, one that binds to 
the immunophilin receptor (the binding domain; pink 
segment, Fig. 1) and another that, together with the 
protein, serves as a composite surface to bind to the 
second protein target (the effector domain; blue segment, 
Fig. 1). Thus, these small organic molecules act as 
‘molecular adapters’, noncovalently binding to the 
immunophilin via the binding domain, and forming a 
composite binding surface composed partly of the effec- 
tor domain, partly of the immunophilin smface, which 
allows binding to the new target, exerting specific bio- 
logical actions. This dual-domain model for the drug 
mechanism of action of these compounds provides 
unique opportunities and challenges in structure-based 
design of ligands for these proteins, and indeed a number 
of studies have already appeared [ 20-271. 
Results and discussion 
Molecular design 
With the aim of designing FKBP12 binding ligands 
whose complexes may or may not bind to the second 
cellular target, we considered structures Sa-c 
(rapamycin-peptides, RAP-Pa-c, shown in Fig. 2). 
Such molecules, which contain the FKBP12-binding 
domain of rapamycin, FK506 and ascomycin, may be 
derived, in principle, from rapamycin (1) by semisyn- 
thesis through the common intermediate 8 (Fig. 3). 
The conformation of rapamycin’s FKBP12-binding 
domain as found by X-ray crystallographic analysis of 
the FKBP12-rapamycin complex [19] was chosen as 
the most desired one for optimum binding. Operating 
on the three structures Sa-c (Fig, 2), and using com- 
puter modeling, we undertook a computational search 
to determine the most suitable tether to constrain the 
binding domain of the designed molecules in this 
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1: Rapamycin 
Mf2 
4: Cyclosporin A 
2 : Ascomycin : R=CH3 
3 : FK506 : R=CH=CH2 
preferred conformation (see Materials and methods for 
details). The designed molecules (5a-c) contained the 
three peptide cassettes shown in Fig. 2. The I)- 
homoPhe-Gly-sarcosine (Sar) cassette allows the for- 
mation of a 21-membered ring that is the same size as 
that found in FK506 and ascomycin, whereas the 
II-homoPhe-(Gly), and D-homoPhe-(Gly), cassettes 
lead to 24- and 27-membered rings, respectively. The 
u-homoPhe group was placed at the ‘right’ end of the 
peptide chain to substitute for the cyclohexyl 
appendage, the u-isomer providing the best fit for the 
C-26 stereocenter of ascomycin (or the C-34 center 
for rapamycin).The sarcosine residue in 5a (RAP-Pa) 
was used to mimic the ethyl group at C-21 of 
ascomycin. A further advantage of the modular nature 
of the designed molecules is that it should allow the 
HO& NHCBz 
q-T-J> 
5a-c 7a-c 
a : HOI&m- NHCBz = H02C-[Sar-Gly-D-homoPhe]-NHCBr 
b : HO&-I-NHCB z = HOzC-[(Gly)3-o-homoPhel-NHCBr 
C : HO&-m- NHCBz = H02C-[(Cly)4-o-homoPhel-NHCBz 
Fig. 1. Structures of the immunosup- 
pressants rapamycin, ascomycin, FK506 
and cyclosporin. The structure of the 
designed rapamycin-based FKBP12 
ligand RAP-Pa is also shown. Pink, 
binding domain; blue, effector domain. 
generation of libraries of compounds with effector 
domains that can bind to either calcineurin or FRAP 
(TOR/RAFTl) or both, as desired. 
Chemical synthesis of designed rapamycin-based ligand 5a 
(RAP-Pa). 
The synthesis of the hybrid compound 5a (RAP-Pa) 
started with compound 8, itself available in two steps 
[28] from rapamycin and proceeded along the lines 
summarized in Fig. 3. Diastereo- and chemoselective 
reduction of compound 8 with lithium selectride (Li- 
selectride) at -78 “C gave a single product, compound 6, 
(96 o/o yield) which was assigned the S-configuration 
based on the non-chelation control Anh-Eisenstein 
model [29]. Silylation of compound 6 with trimethylsilyl 
triflate (TMSOTf) followed by brief exposure to dilute 
acid gave the hemiketal-protected derivative 9 in 92 %I 
yield (-1: 1 mixture of diastereoisomers). The latter COIII- 
pound was then coupled with the peptide chain shown 
as 7a in Fig. 2 using l,3-dicyclohexylcarbodiimide 
(DCC) and catalytic amounts of N,N-4-dimethy- 
laminopyridine (DMAP) to give ester 10 in 85 o/o yield. 
Hydrogenolysis of both the Cbz and Bzl groups followed 
by macrolactamization using BOP reagent and diiso- 
propylethylamine (‘Pr,EtN) gave the desired macrocycle 
ring in 45 % overall yield. Finally, desilylation of the 
latter compound with HF*pyridine furnished the tar- 
geted molecule 5a in 92 ‘% yield (mixture of two 
isomers, -3:l ratio). 
Biological studies 
The binding affinity of compound 5a for FKBP12 was 
measured and compared to those of ascomycin and 
Fig. 2. Molecular design and retrosynthetic analysis of the rapamycin using a competitive binding assay developed at 
designed FKBP12 ligands RAP-Pa-c (5a-c). Sandoz. The IC j0 values for 5a, ascomycin and rapamycin 
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Fig. 3. Synthesis of the designed 
FKBPl2 ligand RAP-Pa (compound 5a). 
Reagents and conditions: (a) see [27], 
(two steps); (b) 3.0 equiv of Li-selec- 
tride, THF, -78 “C, 15 min, 96 %; (c) 
2.2 equiv of TMSOTf, 4.0 equiv of 2,6- 
lutidine, CH,CI,, 0 -C, 15 min, then 
0.1 N HCI: THF (1:25), 25 “C 15 min 
92 %; (d) 2.0 equiv of CBzNH-P-CO,H, 
2.0 equiv of DCC, 0.2 equiv of DMAP, 
CH,CI, 0 “C, 48 h, 85 %; (e) H,, 0.1 
equiv of 10 % palladium on carbon 
(Pd/C), MeOH, 25 “C, 1 h; (f) 3.0 equiv 
of BOP-reagent, 7.0 equiv of rPr,EtN, 
CHCI, (c=O.O02 M), 25 “C, 4 h, 45 % 
(over 2 steps); (g) HF*pyridine, THF, 
25 “C, 24 h, 92 %. 
Me 
6 BrlO’ 
d 
4 
Me 
10 9 
I 5a 
in this assay were found to be 9.6, 0.52 and 0.45 nM, 
respectively. In contrast to rapamycin, however, the con- 
pound showed no activity in IL-h-dependent B-cell 
proliferation and, in contrast to FK506, it exhibited no 
activity in the IL-2 reporter assay. 
These results clearly demonstrate that it is possible to 
design, via molecular modeling, compounds with high 
binding affinity to FKBPl2 using the binding domain of 
rapamycin as an anchor to bind to the protein receptor. 
Furthermore, these studies demonstrate the importance 
of the effector domain for biological activity and open 
the possibility of designing hybrid molecules with both 
FKBP12 binding sites and effector domains for either 
calcineurin or FRAP (TOR/RAFTl). 
Significance 
Immunosuppression is an important area of 
research, the medical benefits of which include the 
ability to transplant organs successfully and to treat 
a variety of immune diseases. The naturally- 
occurring immunosuppressive agents rapamycin, 
ascomycin, FK506 and cyclosporin are important 
clinical or potential clinical agents and are also 
useful biological tools in research into the 
mechanisms of signal transduction in T cells. 
It has previously been suggested that the structures 
of these immunosuppressive agents can be divided 
into two domains, one responsible for binding to 
the cellular receptor, the other responsible for 
interacting with the target. In this study we have 
designed and synthesized a rapamycin-based com- 
pound that has only one of these functional 
domains, the domain responsible for binding to 
FKBP12, the cellular receptor for rapamycin, 
ascomycin and FK506. This designed compound 
does indeed bind tightly to FKBP12, but it does 
not have any of the biological activities of 
rapamycin, ascomycin or FK506. This observation 
confirms the prediction that both the binding 
domain and the effector domain are required to 
produce a biological effect. 
The structure of our designed FKBP-binding com- 
pound is modular. It is therefore now practical to 
generate a large number of these compounds, with 
or without the addition of domains that mimic the 
effector domain. It is conceivable that molecules 
may emerge from such libraries of related com- 
pounds that mimic or antagonize the biological 
actions of rapamycin or FK506/ascomycin, or even 
both. Such compounds may find useful applica- 
tions in biology as tools, or in medicine as 
improved immunosuppressive agents. 
Materials and methods 
Molecular modeling 
All molecular modeling studie\ were corned out using 
BIOSYM Insight 11 (2.2.0) f- lam BIOSYM Technologies, Inc, 
San Diego, CA 92121 or Discover (2.7) on a Silicon Graphics 
terminal (4D-X0) and on an Alliant F2800. The binding 
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domain of rapamycin w3s taken from the published 
FKBP12-rapamycin crystal structure. The structure of the 
21-membered ring 5a was constructed as follows. First a 
peptide bond was made between the C-l carboxyl group of 
fragment 6 and the amino group of v-hornoPhe-Gly-sarco- 
sine. A series of torsions around the (b and Jr angles of the 
peptide fragment were then performed visually on the graphics 
of Insight II to bring the carboxyl group of sarcosine and the 
C-17 hydroxyl group of compound 6 to within bonding dis- 
tance. The CO-O bond was then made. The resulting cyclic 
structure was minimized, first by steepest descent and then by 
conjugate-gradient methods using default parameters with 
coordinates fixed on the entire C,/C,, segment.The resulting 
minimized structure was then superimposed on rapamycin in 
the FKBP12-rapamycin X-ray structure. Rapamycin was 
removed and a new assembly comprising FKHPI 2, structure 5a 
and 53 water molecules (present in the crystal structure) was 
constructed. Molecular dynamics (MD) simulations were 
carried out on this assembly, putting positional constraints on 
the C atoms of all residues of FKBP12 within a 6 A radius 
from the l&and and fixing all atoms beyond that. No cotI- 
straints were set on ligand atoms, whereas the oxygens of all 
water molecules were fixed. The cvff, force field of Discover 
was used for molecular dynamics (MD) simulations. The 
assembly was minimized first for 100 iterations using the steep- 
est descent and then dynamics were initialized at 300 K for 
1000 steps of 1 fs. MD were then resumed for a 20 ps period 
sampling a trajectory at equal 1 ps intervals. Each frame was 
minimized using 100 iterations of conjugate gradients. The 
resulting twenty minimized ligand structures were then super- 
imposed as shown in Fig. 4. The average root-mean-square 
deviation was about 0.1 A. The analysis of the trajectory 
showed that the conformation of the domain remained almost 
fixed, although there were no constraints on it during the 
entire simulation process. Similar results were obtained when 
all constraints were removed from FKBP and the water mole- 
cules. The binding-domain conformation of compound 5a 
remained almost unchanged even when FKBP12 was removed 
and the ligand was ‘soaked’ with water molecules in a sphere of 
10 A radius (a total of 104 water molecules were added) and 
dynamics were carried out on the assembly in a similar fashion 
as described above without any constraints for a 20 ps period. 
Similar MD simulations were carried out compounds 5b and 
5c, which contain 24- and 27-membered rings (Fig. 2) These 
simulation\ revealed considerable deviations ill both the 
binding domain and the entire ligand geometry as the ring size 
and flexibility of the macrocycle increased. The greater 
entropic cost of binding such more flexible rings with FKBP12 
would probably lead to weaker binding. 
These molecular Inodeling studies led us to conclude that the 
21 -membered designed ring system 5a was the best of the three 
compounds examined (5a-c) in terms of its rigidity and ability 
to ‘lock’ the rapamycin/FK506/ascomycin binding domain in 
the desired conformation for complexation with FKBP12. 
Preparation of compound 5a 
Standard synthetic methods and procedures were used to 
convert rapamycin (compound 1) to compound 10 via the 
intermediates shown as 8, 6 and 9 in Fig. 3.The amino acid 
(7.6 mg, 0.01 mliiol) generated from compound 10 by 
hydrogenolysis was dissolved in anhydrous CHCl, (5 ml, 
0.002 M) and stirred under argon with BOP reagent (13 mg, 
0.03 mmol) and diisopropyl ethyl amine (‘Pr,EtN, 12 ~1, 0.07 
rnmol) at 25 “C for 4 h.The reaction mixture was diluted with 
EtOAc (IO ml) and washed with brine (2 x 5 ml).The water 
layer was re-extracted with EtOAc (2 x 5 ml), dried (MgSO,) 
and filtered. Concentration and flash chromatography (silica, 
8C)+lOO % ethyl acetate in petroleum ether) gave trirnethylsi- 
lyl-5a (3.4 mg, 4.5 p,rnol, 45 %) ‘. 15 an amorphous solid. This 
compound (3.4 mg, 4.5 pmol) was dissolved in dry tetrahydro- 
furan (THF) (100 ~1) and treated with HF*pyridine (10 ~1). 
After thin layer chromatographic analysis revealed complete 
desilylation (24 h), the reaction mixture was quenched with 
aqueous saturated NaHC03 (5 ml) and extracted with EtOAc 
(3 x 5 ml).The combined organic layers were dried (MgSO,), 
filtered, concentrated and subjected to flash chromatography 
(silica, EtOAc+S % MeOH in EtOAc) to afford pure 5a 
(2.8 rng, 4.1 pmol, 92 %) as a white amorphous solid. 5a: 
mixture of isomers in DMSO (ca. 3:l) at room temperature; 14 
= 0.12 (major), 0.10 (minor) (silica, EtOAc); high-pressure 
liquid chromatography (HPLC; analytical, Lichrospher 100 
RP-IX, 125 x 4 mm, 5 p,M column): Retention time (RT) 
(min), 10.08 (major), 9.2 (minor) (gradient, 70:30 ‘30:70 
H,O:CH,CN in 20 min, flow rate 1.5 ml min-l, at 40 “C); ‘H 
NMK (500 NHz, DMSO-d,, mixture of isomers, -3:l) 6 8.11 
(major, dd,J=4.8 Hz) and 7.73 (minor, d,J=6.6,3.0 Hz) (total 
1 H, GlyNH); 7.4 (minor, d, 1~7.8 Hz) and 6.67 (major, d, 
Jz7.8 Hz) (total 1 H, hornoPheNH); 7.3-7.1 (m, 5 H, 
Fig. 4. Stereoview of the 20 superim- 
posed energy-minimized structures of 
RAP-Pa (compound 5a) sampled during 
20.ps molecular dynamics simulations 
on an assembly comprising FKBP12, 
RAP-Pa and 53 water molecules present 
in the FKBPl2-rapamycin crystal struc- 
ture. For clarity FKBPIZ and water 
molecules are not shown. 
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aromatic); 6.73 (major, s) and 6.57 (nlinor, s) (total 1 H, 
C,,)OH); 5.04 (major, dq,-Iz6.6, 3 Hz) and 4.92 (minor, dq, 
J=6.6 Hz) (total 1 H, C,,N); 4.96 (III, 1 H, C,H); 4.49 (major, 
d, J=lS.O Hz) and 3.86 (minor, d, ]=I 6.X HZ,) (total 1 H, 
Sara-H): 4.32 (rn, 2 H, C,,lt Cl&); 4.14 (major, m) and 3.85 
(minor, m) (total 2 H, Glycu-H); 3.95 (III, 2 H, Sam-H, C,,H); 
3.54 (major, br d, J=lS.O Hz) and 3.47 (minor, br d, 
Jc15.0 Hz) (total 1 H, C,H); 3.39 (rmjor, dd,j=15.0 Hz) and 
3.31 (minor, dd,J=l5.0 Hz) (total 1 H, C6H); 3.21 (rnajol-, s) 
and 3.19 (minor, s) (total 3 H, OCHj); 3.04 (minor, s) and 2.77 
(major, s) (total 3 H, SnrN-CH,); 2.58 (m, 2 H, PhCH,); 
2.2-1.2 (m, 15 H, “If2 and CH); 1.11 (major, d,J=6.6 Hz) and 
1.0 (minor, d, J=6.6 Hz) (total 3 H, C,,CH,); 0.73 (d, 
J=6.6 Hz, 3 H, C,,CH,); MS(FAB): Calc’d. for 
C,,H,,N,O,,I+Li (M+Li)+: 679, found m/r 679 (M+Li)+. 
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